Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


1 Ann Intern Med
3 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Hepatology
3 J Hepatol
3 J Infect Dis
4 J Viral Hepat
2 Lancet Gastroenterol Hepatol
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Intern Med

  1. AKIYAMA MJ, Norton BL, Arnsten JH, Agyemang L, et al
    Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Ann Intern Med. 2019 Apr 9. pii: 2730524. doi: 10.7326/M18-1715.
    PubMed     Text format     Abstract available

    Eur J Gastroenterol Hepatol

  2. EMORI CT, Uehara SNO, Carvalho-Filho RJ, Amaral AC, et al
    Changing pattern of chronic hepatitis C in renal transplant patients over 20 years.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001404.
    PubMed     Text format     Abstract available

  3. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Text format     Abstract available

  4. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.
    Eur J Gastroenterol Hepatol. 2019;31:24-28.
    PubMed     Text format     Abstract available


  5. LUPBERGER J, Croonenborghs T, Roca Suarez AA, Van Renne N, et al
    Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development.
    Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670.
    PubMed     Text format     Abstract available


  6. JENSEN SB, Fahnoe U, Pham LV, Serre S, et al
    Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30647.
    PubMed     Text format     Abstract available

    J Hepatol

  7. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Text format     Abstract available

  8. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    

  9. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed     Text format    

    J Infect Dis

  10. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed     Text format    

  11. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Text format     Abstract available

  12. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Text format     Abstract available

    J Viral Hepat

  13. CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
    Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
    PubMed     Text format     Abstract available

  14. WEN B, Zhang J, Liu W, Tang P, et al
    HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
    PubMed     Text format     Abstract available

  15. BACK D, Belperio P, Bondin M, Negro F, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
    J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
    PubMed     Text format     Abstract available

  16. TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
    Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
    PubMed     Text format     Abstract available

    Lancet Gastroenterol Hepatol

  17. LAZARUS JV, Palayew A, van Damme P, Hendrickx G, et al
    Eliminating hepatitis C in Europe.
    Lancet Gastroenterol Hepatol. 2019;4:335-336.
    PubMed     Text format    

  18. HICKMAN M, Mandel S, Vickerman P, Miners A, et al
    Hepatitis case finding among migrants in primary care.
    Lancet Gastroenterol Hepatol. 2018 Nov 23. pii: S2468-1253(18)30385.
    PubMed     Text format    

    PLoS One

  19. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0215559.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.